Bridging Fibrosis of the Liver: Causes & Management

Bridging fibrosis is the stage of liver scarring in which bands of scar tissue stretch across the liver’s internal architecture, connecting structures that should be separated. In standard scoring systems used by pathologists, it falls around stage F3 and represents the last major checkpoint before cirrhosis. The stage matters because it is both a warning and an opportunity: the liver is seriously damaged, but the scarring process can still slow, stop, or even partially reverse if the underlying cause is addressed.

What Bridging Fibrosis Actually Looks Like

A healthy liver has a predictable internal layout. Blood flows in through portal tracts, filters through rows of liver cells, and drains out through central veins. In early fibrosis, scar tissue accumulates in limited zones, around portal tracts or along the tiny channels between liver cells. Bridging fibrosis is defined by fibrous septa that lack normal liver cell plates between their collagen fibers and that span from one landmark to another, linking portal tracts to central veins or portal tracts to other portal tracts.¹ These bridges distort blood flow and begin to choke off the liver’s ability to regenerate normally. Once enough bridges form, the liver starts reorganizing into the nodules that define cirrhosis.

Two widely used scoring systems grade the severity. In the METAVIR system, bridging fibrosis is classified as F3. In the Ishak system, which uses a finer scale, stages 3 through 5 capture the spectrum from occasional bridging septa through marked bridging with early nodule formation.² Either way, the clinical message is the same: the liver is one stage away from cirrhosis, and decisions about treatment carry real urgency.

How Scar Tissue Builds Up

The central player in liver scarring is a cell called the hepatic stellate cell. In a healthy liver, stellate cells are quiet and store vitamin A. When the liver is injured repeatedly, these cells activate, transform into collagen-producing machines, and start laying down the extracellular matrix that forms scar tissue.³ Multiple signaling pathways drive this activation, and stellate cells are not acting alone. They recruit portal fibroblasts and bone marrow-derived cells that pile on additional collagen.⁴

Injured or dying liver cells also release signaling molecules called hedgehog ligands that push neighboring stromal cells into a scar-forming state.⁵ This paracrine signaling helps explain why scar tissue clusters around ballooned and dying hepatocytes, a pattern seen in both alcohol-related and metabolic liver disease. Over time, the scar patches merge, condense, and cross-link with elastic fibers, forming the mature septa characteristic of bridging fibrosis.

The Major Causes

Almost any chronic liver insult sustained long enough can progress to bridging fibrosis. The most common causes worldwide are chronic viral hepatitis, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD). Cholestatic conditions like primary biliary cholangitis and primary sclerosing cholangitis are less common but follow their own distinct fibrosis pattern.

Chronic Hepatitis B and C

Chronic hepatitis B affects roughly 250 million people globally, and detecting and quantifying fibrosis is central to deciding who needs antiviral treatment.⁶ Hepatitis C follows a similar trajectory: years of low-grade inflammation gradually drives fibrosis from early stages through bridging and into cirrhosis. In a hepatitis C cohort, about 16% of people with severe (bridging-level) fibrosis developed end-stage liver disease within five years, compared with under 2% of those with mild or no fibrosis.⁷

Alcohol-Related Liver Disease

Alcohol causes a distinctive pattern of scarring. The enzymes that metabolize ethanol, particularly CYP2E1, are concentrated around the central veins. This means the earliest damage and scar tissue appear in the centrilobular zone. As drinking continues, the scar tissue radiates outward, eventually bridging from central veins to portal tracts and between adjacent central veins.⁵ Ongoing alcohol abuse accelerates the condensation of these septa into dense, cross-linked collagen, making the scarring harder to reverse the longer it persists.

Metabolic Liver Disease (MASLD/MASH)

Fat accumulation in the liver from metabolic dysfunction can trigger inflammation (steatohepatitis), which drives the same stellate-cell activation pathway. Animal models show a stepwise progression: fat deposits appear first, steatohepatitis and early fibrosis follow, advanced bridging fibrosis develops further along, and cirrhosis is the final stage.⁸ Because MASLD is now the most common chronic liver disease in many countries, it has become a leading driver of bridging fibrosis in clinical practice.

Cholestatic Liver Diseases

In conditions like primary biliary cholangitis and primary sclerosing cholangitis, the injury starts around the bile ducts rather than in the liver cells themselves. Portal fibroblasts near the bile ducts are the first responders to biliary damage, while hepatic stellate cells are recruited later as the fibrosis extends into bridging patterns.⁹ Biliary fibrosis at the bridging stage is associated with worse clinical outcomes and higher histologic severity scores.

How Bridging Fibrosis Is Detected

Liver biopsy remains the reference standard, but it has well-known problems. The procedure samples a tiny cylinder of tissue, and fibrosis is not evenly distributed. In one study of patients with fatty liver disease, about a third of those who had bridging fibrosis on one biopsy sample showed only mild or no fibrosis on a second sample taken from the other lobe.¹⁰ Similarly, in chronic hepatitis C, roughly a third of patients had at least a one-stage discrepancy between right and left lobe biopsies.¹¹ Biopsy also carries cost and a small risk of complications.¹²

Because of these limitations, non-invasive tests have become front-line tools for staging fibrosis. They fall into two categories: blood-based scores and imaging-based stiffness measurements.

Blood-Based Scoring Tools

The FIB-4 index and NAFLD Fibrosis Score (NFS) are calculated from routine lab work and patient demographics. They are widely available and cost nothing beyond the blood draw you are already getting. In hepatitis C, FIB-4 at a lower cutoff had a diagnostic odds ratio of about 14 for identifying advanced fibrosis (F3 or higher) across dozens of studies.¹³ However, these simple scores struggle in certain populations. In patients with type 2 diabetes, for example, both FIB-4 and NFS produce unacceptably high rates of false negatives and false positives.¹⁴

The Enhanced Liver Fibrosis (ELF) test, which measures three direct markers of matrix turnover, performs better in this context. Its diagnostic accuracy remained consistent in patients with and without diabetes, and it outperformed FIB-4 and NFS across studied populations.¹⁵ The trade-off is that ELF is a specialized lab test and is not available everywhere.

Imaging-Based Stiffness Measurements

Vibration-controlled transient elastography (commonly known by the brand name FibroScan) measures liver stiffness by sending a shear wave through the organ. Stiffer tissue means more fibrosis. A meta-analysis in fatty liver disease found that for detecting fibrosis at stage F3 or higher, transient elastography reached about 94% sensitivity and 91% specificity.¹⁶ In a large individual study, the best cutoff for F3 or higher was about 9.7 kPa.¹⁷

Magnetic resonance elastography (MRE) uses an MRI scanner to map stiffness across the entire liver rather than a single spot. This broader sampling reduces the variability problem that plagues both biopsy and point-based elastography. MRE has demonstrated very high accuracy for detecting stage F3 or higher, with cutoff values around 3.3 kPa on MRE’s scale (which uses a different unit than FibroScan).¹⁸ Its main downsides are cost and availability; not every medical center has an MRE-capable scanner.

Why the F3 Stage Is a Clinical Inflection Point

Bridging fibrosis carries meaningfully different risks than full cirrhosis, and understanding the gap matters for treatment decisions and expectations. A large comparative study found that patients with stage F4 (cirrhosis) had a five-year probability of any decompensation event of about 38%, compared with roughly 14% for those at stage F3. Five-year survival was also lower in the cirrhotic group (about 80%) than in the bridging fibrosis group (about 93%).¹⁹ The risk of liver cancer was similar between the two stages in that study, though in the hepatitis C cohort mentioned earlier, the jump in liver cancer risk came primarily at the cirrhosis stage rather than at F3.⁷

Beyond the liver itself, advanced fibrosis is tied to cardiovascular risk. In one study of patients with fatty liver disease, about 20% of those with advanced fibrosis experienced a cardiovascular event, compared with roughly 7% of those without advanced fibrosis.²⁰ Portal hypertension, the increase in pressure within the liver’s blood supply that drives many complications, can also begin at the F3 stage, although it is more reliably present once cirrhosis develops.²¹

Managing the Underlying Cause

No single drug reverses fibrosis on its own. The most consistently effective strategy is removing whatever is injuring the liver in the first place. The specific approach depends entirely on the cause.

Viral Hepatitis

For hepatitis C, direct-acting antiviral drugs can clear the virus in most patients within weeks. Once the virus is gone, fibrosis is a dynamic process that can begin to reverse. In one study, about 86% of patients treated with direct-acting antivirals showed a reduction in liver stiffness, and roughly 22% improved by at least one fibrosis stage.²² Even patients who have already reached cirrhosis benefit from viral clearance: it halts disease progression, reduces the need for transplant, and improves survival.²³ For hepatitis B, long-term antiviral suppression similarly slows fibrosis progression, though true viral eradication is harder to achieve.

Alcohol Cessation

Stopping alcohol intake removes the metabolic insults that drive centrilobular scarring. The liver’s ability to heal depends on how much cross-linked, mature scar tissue has already formed. Earlier cessation gives a better chance of regression, but even advanced fibrosis can improve over time once alcohol is eliminated. No medication can substitute for abstinence in alcohol-related liver disease; it is the single most effective intervention.

Weight Loss in Metabolic Liver Disease

For people with MASLD or MASH, sustained weight loss is the cornerstone of management. Evidence suggests that losing at least 10% of body weight can stabilize or reverse fibrosis, while more modest losses of 5-7% improve fat accumulation and inflammation without necessarily changing fibrosis stage.²⁴ Achieving and maintaining a 10% weight loss is challenging for most people, which is why pharmacologic options have become important.²⁵

New and Emerging Drug Therapies

For decades, there were no approved drugs specifically targeting liver fibrosis from metabolic causes. That changed with resmetirom, a thyroid hormone receptor-beta agonist that acts selectively on the liver to reduce fat accumulation and inflammation. Resmetirom became the first drug approved specifically for non-cirrhotic MASH in adults with moderate to advanced fibrosis, meaning F2 to F3.²⁶ Its pivotal trial showed resolution of steatohepatitis without worsening of fibrosis.²⁷ Semaglutide, a GLP-1 receptor agonist already well known for diabetes and obesity, has also received conditional approval for MASH, reflecting a rapidly expanding treatment landscape.²⁸

These drugs are not cures for fibrosis itself. They improve the metabolic environment that drives scarring, giving the liver’s own repair systems a chance to work. Neither drug is approved for cirrhotic patients, so from a fibrosis standpoint, they are most relevant precisely at the bridging fibrosis stage where intervention can prevent progression to irreversible disease.

How the Liver Reverses Its Own Scarring

Fibrosis regression was once considered impossible. The thinking was that scar tissue, once deposited, was permanent. That view has shifted substantially. When the injurious trigger is removed, the liver can remodel scar tissue through a set of coordinated biological processes.²⁹

Macrophages, a type of immune cell, play a dual role. During active injury, one subset promotes inflammation and drives fibrosis forward. When the injury stops, a different subset takes over. These restorative macrophages break down scar tissue by secreting enzymes called matrix metalloproteinases (MMPs), clear dead cells, and produce anti-inflammatory signals that quiet the stellate cells.³⁰ Reprogramming macrophages toward this restorative state is now seen as closely linked to fibrosis resolution.³¹ In animal studies, the reparative macrophage population expands during fibrosis regression and actively degrades extracellular matrix.³²

That said, reversal has limits. The longer scar tissue has been in place and the more extensively it has been cross-linked with elastic fibers, the harder it is for enzymes to break down. Bridging fibrosis with mature, dense septa is more resistant to regression than earlier-stage fibrosis with loose collagen. This is part of why timing matters so much: a patient treated at F3 has better odds of meaningful improvement than one treated at established cirrhosis.

Experimental Approaches Targeting Stellate Cells Directly

Because hepatic stellate cell activation is the bottleneck in scar formation, researchers are exploring ways to silence these cells at the molecular level. One area of interest involves microRNAs, tiny molecules that regulate gene expression. Certain microRNAs that are normally abundant in healthy liver tissue become depleted during fibrosis, and restoring them in animal models has shown promising results.³³ In one preclinical study, delivering a combination of two specific microRNAs directly to stellate cells using targeted nanocarriers reduced expression of collagen and other fibrosis-related genes, improving liver function in fibrotic rats.³⁴

Separately, researchers have identified focal adhesion kinase (FAK) as a molecule involved in stellate cell activation. Blocking FAK activity in mouse stellate cells nearly completely prevented the expression of collagen and activation markers triggered by a key pro-fibrotic signal.³⁵ These approaches remain in the lab for now, but they illustrate a broader shift toward treating fibrosis as an active, targetable process rather than passive structural damage. The gap between showing that something works in a rodent liver and proving it is safe and effective in people is large, and no stellate-cell-targeted therapy has reached clinical approval. Still, the direction of the research is encouraging for patients with fibrosis who may eventually have options beyond treating the underlying disease alone.